ADAR1 Capital Management LLC decreased its stake in Merus (NASDAQ:MRUS - Free Report) by 46.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,460 shares of the biotechnology company's stock after selling 71,826 shares during the period. ADAR1 Capital Management LLC owned 0.12% of Merus worth $3,425,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently made changes to their positions in the stock. Wells Fargo & Company MN increased its position in Merus by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 300 shares during the period. Avior Wealth Management LLC acquired a new stake in shares of Merus during the fourth quarter worth $76,000. MML Investors Services LLC bought a new position in Merus during the third quarter worth $206,000. Gordian Capital Singapore Pte Ltd raised its stake in Merus by 10.4% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company's stock worth $250,000 after buying an additional 470 shares during the last quarter. Finally, HighTower Advisors LLC lifted its holdings in Merus by 10.9% in the fourth quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company's stock valued at $337,000 after buying an additional 789 shares during the period. 96.14% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
MRUS has been the subject of a number of recent analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $83.00 price target on shares of Merus in a report on Wednesday. Bank of America lowered their target price on Merus from $73.00 to $70.00 and set a "buy" rating for the company in a report on Monday, March 10th. HC Wainwright restated a "buy" rating and set a $85.00 price target on shares of Merus in a report on Monday, March 3rd. Guggenheim reiterated a "buy" rating and issued a $109.00 price objective on shares of Merus in a research note on Friday, March 28th. Finally, Piper Sandler started coverage on shares of Merus in a research note on Thursday, February 13th. They set an "overweight" rating and a $84.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $85.31.
Check Out Our Latest Analysis on Merus
Merus Trading Up 8.7 %
NASDAQ MRUS traded up $3.35 during trading hours on Friday, hitting $41.97. The company's stock had a trading volume of 832,258 shares, compared to its average volume of 712,988. The company's 50-day simple moving average is $43.65 and its two-hundred day simple moving average is $45.25. The company has a market capitalization of $2.90 billion, a PE ratio of -10.63 and a beta of 1.02. Merus has a 52 week low of $33.19 and a 52 week high of $61.61.
Merus (NASDAQ:MRUS - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. Research analysts anticipate that Merus will post -3.85 EPS for the current fiscal year.
About Merus
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Read More
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
